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a b s t r a c t
Fulminant myocarditis (FM) is an inﬂammation of the myocardium characterized by
progressive acute heart failure leading to cardiogenic shock that develops over several
hours. In this article, we present a case of a female patient with acute fulminant lymphocytic
myocarditis who was successfully treated with biventricular MCS.
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All rights reserved.




Fulminant myocarditis (FM) is an inﬂammation of the myocar-
dium characterized by progressive acute heart failure that
develops over several hours or days [1–3]. Compared with acute
myocarditis, following differences are identiﬁed in FM, in
addition to the rapid progression of the heart failure: common
signs of viral infection preceding the manifestation of the
disease by 2–4 weeks, more frequent disorders of the ventricular
conduction, atrioventricular (AV) blocks and ventricular* Corresponding author. Department of Cardiovascular Surgery, Institu
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cardiac-speciﬁc enzymes; and more frequent hepatorenal
dysfunction. Echocardiography reveals the characteristic non-
dilated left ventricle with thicker walls and reduced ejection
fraction [4]. Diagnosis of FM by means of coronary angiogram
excludes acute coronary syndrome, and the use of an
endomyocardial biopsy (EMB) identiﬁes and differentiates
forms that are poorer in terms of prognosis, such as giant
cell or necrotizing eosinophilic myocarditis, from benign
forms such as acute lymphocytic or hypersensitivity myocar-
ditis [3,5].te for Clinical and Experimental Medicine (IKEM), Vídeňská 1958/9,
081 362.
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tivity myocarditis has been signiﬁcantly improved by the new
developments in the drug treatment of acute heart failure and/
or the implantation of a mechanical circulatory support (MCS)
device, since, after the initial critical phase had been managed,
these FMs have a benign prognosis, leading most commonly to
complete recovery. In this report, we present a case of a female
patient with acute fulminant lymphocytic myocarditis who
required biventricular MCS in the initial phase of cardiogenic
shock, accompanied by unstable ventricular tachycardia.
2. Case report
A 53-year-old, non-smoking female patient with a body mass
index (BMI) of 27 kg/m2, a history of thyroid disease, and no
other signiﬁcant medical history was referred to our clinic with
cardiogenic shock accompanied by persistent ventricular
tachycardia episodes. The patient was admitted to the
respective cardiac clinic on February 17, 2011, at 3:00 p.m. in
a precollapse state following 2 days of viral infection, with
overall malaise, difﬁcult breathing, and chest pain. The initial
electrocardiogram (ECG) showed sinus rhythm with heart rate
of 84 beats/min, left anterior hemiblock, right bundle branch
block, and a higher-degree intermittent AV block; laboratory
results detected positive troponin I levels (>40 mg/L). Coronary
angiography, performed to exclude a coronary event, showed
regular ﬁndings. However, the transthoracic echocardiogram
(TTE) showed dysfunction of the non-dilated left ventricle (LV):
LV end-diastolic diameter (LVEDD) = 52 mm; wall thickness of
interventricular septum (IVS) = 10 mm; posterior wall thick-
ness = 11 mm; ejection fraction (LVEF) = 35% and signs of
dyssynchrony. The patient was transferred to our facility on
February 18, 2011, at 2:00 p.m. because of cardiogenic shock,
requiring a combination of inotropic support (norepinephrine
0.1 mg/kg/min, dobutamine 5 mg/kg/min), ongoing slow ventric-
ular tachycardia of 130/min (Fig. 1), and incipient alteration of
organ function. The patient was conscious, short of breath at
rest, hypotensive (85/40 mmHg) and displayed signs of periph-
eral vasoconstriction. Chest ﬂuoroscopy demonstrated signs of
interstitial lung edema and non-dilated heart shadow. Echocar-
diography revealed reduced systolic LV function (LVEF = 20%,
LVEDD = 56 mm, IVS = 9 mm), moderate functional mitralFig. 1 – ECG at admission showing ventricular tachycardia
130/min.regurgitation, slightly reduced right ventricle (RV) function,
and increased ﬁlling pressures in both ventricles. Laboratory
results revealed signiﬁcantly increased levels of B natriuretic
peptide (BNP) (1595 ng/L) and troponin I (45.9 mg/L), aspartate
aminotransferase (AST) = 4.72 mkat/L, alanine transaminase
(ALT) = 1.95 mkat/L, creatinine = 80.4 mmol/L, urea = 10.0 mmol/
L, C-reactive protein (CRP) = 30.2 mg/L, glycemia = 7.9 mmol/L,
hemoglobin (Hgb) = 117 g/L, and lactate = 2.2 mmol/L. The con-
dition was diagnosed as FM with a rapid progressive syndrome
of low cardiac output, and the urgent implantation of short-
term mechanical cardiac support (MCS) was indicated. The
CentriMag ventricular assist system (Levitronix LLC; Waltham,
Mass) was used.
The patient was transferred to the operating room at 4:00 p.
m. in critical condition. Paroxysmal supraventricular tachy-
cardia (SVT) (150/min.) resistant to repeated deﬁbrillation
occurred following anesthesia. Critical systemic hypotension
required indirect and, following longitudinal sternotomy,
direct heart massage through the anterior mediastinum. Bolus
injections of norepinephrine were administered to maintain at
least a minimum perfusion pressure. After heparin adminis-
tration, extracorporeal circulation was introduced in a
standard way. Vascular prostheses (Vascutek 8) were applied
ﬁrst to ascending aorta and then to the pulmonary artery; two
tobacco-pouch sutures with pericardial pads were applied to
free walls of both atria. Cannulas of the CentriMag left and right
ventricular assist device (LVAD and RVAD, respectively) were
introduced and the systems were voided of air. Gradually, the
activities of both CentriMag devices were initiated (LVAD,
3700 rpm with cardiac output (CO)  5.5 L/min; RVAD, 3600 rpm
with CO = 4.0–4.5 L/min). Extracorporeal circulation was used
for 115 min, and protamine was administered; possible bleeding
sources were reviewed; hemostasis was achieved; 3 drains were
introduced; deﬁnite suture was postponed; vasopressor support
by means of norepinephrine oscillated at approximately 0.3 m/
kg/min; and maximum lactate level was 6.3 mmol/L. Bleeding
revision was performed on postoperative day (POD) 1, deﬁnite
suture on POD 2, and extubation on POD 3 after discontinuation
of inotropic support.
Myocardial RV biopsy conﬁrmed acute lymphocytic myo-
carditis (20 lymphocytes/mm2) accompanied with plaques of
myonecroses and minimum interstitial necrosis (Fig. 2).Fig. 2 – Biopsy showing interstitial inflammatory infiltrate.
Fig. 3 – Biopsy showing T lymphocyte infiltration (CD3
antibody).
Fig. 4 – Inflammatory cellulization in regression and
fibrosis.
Fig. 5 – Fibrous tissue multiplication.
c o r e t v a s a 5 6 ( 2 0 1 4 ) e 4 3 6 – e 4 4 0e438Immunohistochemical examination detected massive pres-
ence of T-lymphocytes (anti-CD3 positive cells) and the
presence of macrophages (Fig. 3). A frozen cardiac sample
was also sent for virology examination; the polymerase chain
reaction (PCR) test failed to detect the etiologic agent. A slight
Epstein–Barr positivity did not explain the ongoing acute
myocarditis. Other cardiotropic viruses were negative (herpes
simplex virus, human herpesvirus 6, cytomegalovirus, and
enteroviruses). It was not possible to establish disease etiology
using a panel of serologic examinations for cardiotropic
agents. A basic immunologic examination was performed,
which excluded systemic autoimmune disease or vasculitis;
only antibodies against thyroglobulin and thyroid peroxidases
were detected as positive, with a regular thyroid-stimulating
hormone (TSH) value that was compatible with the diagnosis
of autoimmune thyroiditis at the euthyrosis stage.
Further postoperative course displayed no complications.
Echocardiography performed on POD 7 detected a slight
increase in LVEF to the value of 25–30%; systolic RV function
was slightly reduced. A further improvement of the non-
dilated LVEF (LVEDD = 44 mm) to the value of 45–50% was
detected on POD 12, as well as minor AV regurgitation and
insigniﬁcant pericardial effusion. After the reduction of MCS
rounds with the ﬂow rate of 2.0 L/min, LV remained undilated,
EF = 45% with accentuated paradoxical IVS movement and
hypokinetic anteroseptal wall. The total duration of biven-
tricular CentriMag support was 20 days. Satisfactory clinical
features, improvement of laboratory results, and satisfactory
systolic function of both ventricles according to TTE examina-
tion enabled us to perform CentriMag explantation on March
11, 2011. The hemodynamic situation in early phases after
explantation was stable; only 5 mg/kg/min dobutamine was
administered after explantation. Follow-up RV biopsy per-
formed during explantation detected hemorrhagia in the
epicardial area as well as regression of round-cell inﬂamma-
tory cellulization, mild interstitial ﬁbrosis, and isolated
granulocytes in the ﬁbrous tissue, with no signs of myocyte
damage. The overall conclusion was regressive myocarditis
with a minor degree of ﬁbrosis (Figs. 4 and 5).The course of post-MCS-explantation treatment was free
from complications – an ECG detected sinus tachycardia of
104/min and incomplete RBBB. Chronic heart failure medica-
tion was provided to the patient due to the threshold LV
systolic function (Table 1); maximum beta-blocker and
angiotensin-converting-enzyme (ACE-) inhibitor dosages were
limited due to the threshold systemic blood pressure. Table 1
shows the development of cardiac markers and some
echocardiographic and biochemical indicators before MCS
implantation, during unloading of both ventricles, in the
period close to MCS explantation, and during long-term
patient follow-up in the outpatient setting. At present, the
patient has been followed for 24 months in the outpatient
department without any signiﬁcant breathlessness during
regular exercise. However, the patient reported decreased
performance compared to the period before the disease and
decreased tolerance of medication used to treat chronic heart
failure due to inclination to hypotension with blood pressure
of 100–110/70 mmHg as a response to a minor maintenance
Table 1 – Biochemical and echocardiographic markers development before and after MCS implantation.
Before MCS implantation After MCS implantation
Date 2/18/2011 21.2. 25.2. 3.3. 8.3. 10.3. 15.3. 21.3. 26.4. 21.6. 6.9. 5/29/2012
Value Unit Biochemistry
CRP mg/l 30.2 110.6 58.7 95.1 34.2 85.5 31.2 47.7 1.8 0.5 0.5
Troponin I mg/l 45.9 0.47 0.06 <0.03 <0.03
BNP ng/l 1596 487.5 363.9 205.2 83.3 34.4 50.6
AST mkat/l 4.72 1.91 0.77 0.48 0.57 0.47 0.4 0.56 0.57 0.44
Urea mmol/l 10 9.4 5.8 3.4 3.4 2.9 4.2 2.9 5.5 5.3 5.6
Echocardiography
LVEDD mm 56 46 48 44 47 45 54 54 53
IVS mm 9 11 11 9 8 8 8 9
ZS mm 9 10 11 9 9 8 8 8
LVEF % 20 25–30 45–50 45–50 50–55 50–55 55 50–55 55–60
c o r e t v a s a 5 6 ( 2 0 1 4 ) e 4 3 6 – e 4 4 0 e439dose of beta-blocker (bisoprolol 2.5 mg daily), ACE-inhibitor
(ramipril 1.25 mg daily), and spironolactone. Three months
following MCS explantation, the BNP levels returned to
normal; there is also evidence of normal levels of cardiac-
speciﬁc troponin I enzyme after 6 months. Echocardiography
follow-up examinations revealed long-term threshold non-
dilated LV systolic function, with EF of 50–55% and hypoki-
netic anteroseptal wall, and threshold RV systolic function,
with no signs of pulmonary hypertension at rest. Good LV
function was conﬁrmed also by follow-up MRI scan 6 months
after explantation. The patient underwent repeated spiroer-
gometry testing, which detected a slightly improving but
decreased exercise tolerance (maximum O2 consumption was
20.4 ml/kg/min, i.e., 73% of the normal value 20 months after
explantation), with an adequate ventilation response to
exercise without hyperventilation, as well as a 6-min walk
test in which she repeatedly walked more than 500 m, slightly
exceeding the standard for her age and gender. After a one-
year incapacity for work, the patient returned to work where
she exercises in her profession.
3. Discussion
We report on a case of a successful treatment of pharmacologi-
cally resistant cardiogenic shock accompanied by paroxysmal
ventricular tachycardia in a female patient with lymphocytic
FM. Treatment during the acute phase by means of biventricular
Levitronix CentriMag MCS resulted in recovery of the LV systolic
function and arrhythmogenic substrate stabilization.
The FM course is characterized by a rapid progression of
acute bilateral heart failure toward the phase of cardiogenic
shock. It can also be complicated by serious rhythm
disturbances of the heart such as AV blocks and ventricular
arrhythmias. Thorough monitoring of patients with FM in a
comprehensive cardiac clinic disposing of MCS is a prerequi-
site for the successful treatment of its initial phase to bridge
the episodes of pharmacologically resistant cardiogenic shock.
Extracorporeal membrane oxygenation (ECMO) and paracor-
poreal biventricular MCS are the most common types of MCS
used in these conditions [3].
Endomyocardial biopsy has a decisive effect on the
treatment of these patients. The detection of giant cell ornecrotizing eosinophilic myocarditis is an indication for
immunosuppressive treatment [1–3,6–9], as well as a second-
ary indication for biventricular MCS implant. Cooper et al.
described successful immunosuppressive treatment adminis-
tered in a female patient with necrotizing eosinophilic
myocarditis treated by paracorporeal MCS, which led to the
restoration of LV systolic function [8].
However, the restoration of LV systolic function in patients
with fulminant forms of lymphocytic myocarditis is to be
expected at approx. 2 weeks; therefore, circulatory instability
in these cases may be bridged by means of a short-term MCS
such as ECMO.
Initial clinical state prior to MCS is another factor. In
particular, the use of ECMO is favorable in patients with
cardiogenic shock and insufﬁcient oxygenation with artiﬁcial
ventilation [3], as well as in patients with unclear neurological
status following cardiopulmonary resuscitation as bridge-to-
decision. Biventricular paracorporeal MCS is recommended in
patients with critically reduced cardiac index (1.5 L/min m2)
and possibly in patients with hemodynamically signiﬁcant
ventricular arrhythmias and signs of advanced LV remodeling,
indicating the need of long-term MCS [10]. Past published results
showed that paracorporeal MCS procedure outnumbered the
ECMO technique (n = 155, 46% vs. 24%) [11]; however, Mirabel
et al. [12] recently published evidence of a signiﬁcantly increased
use of ECMO as opposed to paracorporeal MCS (n = 41, 15% vs.
85%). However, ECMO is the predominantly used procedure in
children with FM [13,14]. Survival of 68–73% of adult patients
after MCS discontinuation has been reported [11,12,15,16], with
the restoration of LV function as opposed to the necessity to
perform heart transplant. In children, previous publications
have reported 46% survival after MCS discontinuation [13].
Recently published results report successful bridging of the
acute phase in as many as 75% of cases [14], with the restoration
of LV function in 43% of the patients, whereas only 32% of these
patients needed heart transplant [14]. The short period between
symptom manifestation and MCS implantation seems to be the
most signiﬁcant indicator of successful restoration of LV
function in FM patients after MCS implant. Atluri et al. [17]
report a signiﬁcantly shorter interval in patients with restored
LV function compared to the rest of the patient group (median of
7 days vs. 21 days). These results support the use of MCS in FM
patients with pharmacologically resistant acute cardiac failure.
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In patients with rapidly progressing heart failure refractory to
drug treatment, implantation of short-term mechanical
cardiac support may help to bridge the period of hemodynamic
instability. This is particularly true for FM patients in whom
the threshold for MCS use is lower than that in cases of acute
heart failure caused by other reasons. This procedure, together
with the immediate transfer of the patient into a respective
cardiac clinic, should be the chosen method.
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